DOW JONES23,078.58+398.59 1.76%
S&P 5002,705.36+41.68 1.56%
NASDAQ7,963.93+50.69 0.64%

Checkpoint Therapeutic Receives FDA Feedback Confirming Co.'s Registration Path For Cosibelimab In Metastatic Cutaneous Squamous Cell Carcinoma Based On Efficacy And Safety Data From Phase 1 Clinical Trial

Benzinga · 01/13/2020 13:18